Bristol-Myers Lung-Cancer Drug Disappoints in Trial AnalysisBy and
Drugmaker says trial design may have influenced negative data
Bristol-Myers results contrast with Merck’s in similar group
Bristol-Myers Squibb Co.’s immune-based therapy Opdivo fell short of already low expectations in study results that throw into question whether the drug can help lung-cancer patients who’ve just been diagnosed.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.